17 November 2020

Dr. Christelle Haziza discusses the types of clinical studies that are conducted as a part of our Disease Risk Reduction Studies.

"We have definitely demonstrated that you have a reduction in exposure to toxicants when you switch to the product."

Dr. Christelle Haziza, Director Clinical Science and Biostatistics

Below is the transcript of the video:

We are designing all the clinical studies to demonstrate scientific evidence on our product and especially to demonstrate the likelihood of reducing the risk of diseases in humans.  In fact, it’s pretty broad, and we have three main kinds of studies.

I would call the first type of study as a biomarker type study, where we will assess biomarkers to toxicants that you mainly find in the cigarette smoke as an example and try to measure them in the human body. We are also measuring biomarkers of the biological health like as an example, lipid metabolism, coagulation, and inflammation to follow up on biological effect when you switch to the product. This is the first type of study.

The second type of study is much more dedicated to understanding short term health benefits. You can think about your ability to exercise or skin benefit when switching to our product versus continuing cigarette smoking.

I would think that the third type of study would be mainly dedicated to understanding what the impacts are when you switch to the product in people you have already been diagnosed with a disease like cardiovascular disease or respiratory disease as an example.

When we analyze the aerosol chemistry of our product, we have demonstrated that the aerosol contains approximately 95% lower [average levels of] toxicants when you compare it to the reference cigarette,* but this is at the aerosol chemistry level from a design perspective. We wanted to make sure that when a human is switching from cigarette to these products, we can also find a lower reduction in the human body. To do so, we are using biomarkers of exposure that we can follow into body metrics, like blood or urine, to make sure that when you are using the product you have a reduced exposure to these toxicants.

The first conclusion across all of the study of the result were fully coherent independently of the population, the country, or the intensity of smoking before switching to the product. We have definitely demonstrated that you have a reduction in exposure to toxicants when you switch to the product. And as you may know, exposure to toxicant leads to damaging organs or even some of them are known to be carcinogenic, [which means] they may help to develop cancer, so you may imagine that if you have a lower exposure and you damage less organ, you have a likelihood of reduction of risk of disease and harm.

 * Excluding nicotine, the aerosol of our leading heated tobacco product contains on average 95% lower levels of toxicants compared to reference cigarette.

Sharon Carty for Page Overview

Watch Sharon Carty outline the planning that goes with disease risk reduction studies


Watch Dr.Haziza discuss the future of our Disease Risk Reduction Studies

Sharon Carty Page Overview 2

Watch Sharon Carty explain the importance of disease risk reduction studies